Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?

IF 1.3 Q4 RHEUMATOLOGY European journal of rheumatology Pub Date : 2023-01-01 DOI:10.5152/eurjrheum.2023.22012
Yiannis Ioannou, Timothy Beukelman, Miranda Murray, Doruk Erkan
{"title":"Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?","authors":"Yiannis Ioannou,&nbsp;Timothy Beukelman,&nbsp;Miranda Murray,&nbsp;Doruk Erkan","doi":"10.5152/eurjrheum.2023.22012","DOIUrl":null,"url":null,"abstract":"<p><p>Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"10 1","pages":"39-44"},"PeriodicalIF":1.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/61/9f/ejr-10-1-39.PMC10152079.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/eurjrheum.2023.22012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抗磷脂综合征的发病率:目前是否可能估计?
抗磷脂综合征是一种系统性自身免疫性疾病,以血管血栓形成和/或产科事件为特征,与抗磷脂抗体持续升高有关。抗磷脂综合征通常被认为是一种罕见的疾病,但由于抗磷脂抗体相关的临床表现多样,抗磷脂抗体阳性的定义不一致,对该疾病的认识不足,以及基于人群的研究有限,因此真实的发病率尚不确定。已公布的抗磷脂综合征发病率估计范围约为每10万人年2至80例。有针对性的文献回顾和应用的方法进行,以得出最佳的可用估计。观察到已发表文献的显著局限性,其中一些已被先前报道。据估计,美国普通人群中抗磷脂综合征的发病率约为每10万人年7.1至13.7例。尽管这一估计可能比先前报道的估计更准确,但仍需要大规模的、基于人群的、合理坚持抗磷脂综合征分类标准的研究来进一步完善对抗磷脂综合征发病率的估计。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
56
审稿时长
7 weeks
期刊最新文献
Bullous Cutaneous Lupus Erythematosus and Class V Lupus Nephritis: Rare Concurrence. Comparison and Significance of Contrast-Enhanced Computed Tomographic Findings of Large-Vessel Vasculitis Before and After Treatment: Differences Between Takayasu Arteritis and Giant Cell Arteritis. Evaluation of Rheumatologists' Teledermatology Practices and Perspectives. Factors Associated with the Development of Anti-drug Antibodies to TNFi and the Consequences for Axial Spondyloarthritis: A Two-year Follow-up Study. Homeopathy for Rheumatological Diseases: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1